Salvage Chemotherapy for AML Relapsing During Daunorubicin-Cytarabine Treatment
For AML patients who relapse during daunorubicin-cytarabine chemotherapy, the next treatment should be high-dose cytarabine (HiDAC)-based salvage regimens—specifically FLAG-IDA, IDAC with or without anthracycline, or MEC—followed by allogeneic hematopoietic cell transplantation (HCT) as definitive consolidation. 1
Primary Salvage Regimen Options
The 2017 ELN guidelines explicitly outline three main salvage chemotherapy regimens for relapsed/refractory AML patients who are candidates for intensive therapy 1:
FLAG-IDA (Preferred for Younger Patients)
- Fludarabine 30 mg/m² IV days 2-6
- Cytarabine 1500-2000 mg/m² IV over 3 hours (starting 4 hours after fludarabine) days 2-6
- Idarubicin 10 mg/m² IV days 2-4
- G-CSF 5 mcg/kg SC days 1-5
- Dose reduction for patients >60 years: fludarabine 20 mg/m², cytarabine 500-1000 mg/m², idarubicin 8 mg/m² 1
IDAC ± Anthracycline
- Cytarabine 1000-1500 mg/m² IV over 3 hours every 12 hours days 1,3,5 (500-1000 mg/m² if >60 years)
- With or without: daunorubicin 45-60 mg/m² days 1-3, idarubicin 8-10 mg/m² days 3-5, or mitoxantrone 8-10 mg/m² days 1-3 1
MEC Regimen
- Mitoxantrone 8 mg/m² days 1-5
- Etoposide 100 mg/m² days 1-5
- Cytarabine 1000 mg/m² days 1-5 1
Critical Decision Points
Age and Performance Status
The choice between these regimens depends heavily on:
- Younger patients (<60 years): FLAG-IDA or full-dose IDAC with anthracycline are preferred 1
- Older patients (≥60 years): Dose-reduced FLAG-IDA or IDAC 500-1000 mg/m² with consideration of cardiac function 1
- Cardiac dysfunction: MEC regimen avoids anthracyclines 1
Duration of First Remission
This is the most important prognostic factor:
- CR1 duration <6 months: Extremely poor prognosis; consider investigational agents or proceeding directly to allogeneic HCT if minimal disease burden can be achieved 2
- CR1 duration 6-18 months: Standard salvage chemotherapy followed by allogeneic HCT 2
- CR1 duration >18 months: Better response to salvage therapy; still requires allogeneic HCT for cure 2
Cytogenetic Risk at Diagnosis
- Favorable-risk cytogenetics: Better salvage response rates, but allogeneic HCT still recommended 2
- Adverse-risk cytogenetics: Poor salvage outcomes; early HLA typing and donor search essential 1, 2
Mandatory Next Steps
Immediate Actions
- HLA typing and donor search: Must be initiated immediately, as allogeneic HCT is the only curative option for relapsed AML 1, 2
- Consider matched sibling, matched unrelated, or alternative donors (haploidentical, cord blood) 1
Post-Salvage Strategy
Allogeneic HCT is the definitive consolidation therapy once remission is achieved with salvage chemotherapy 1, 2. The goal of salvage chemotherapy is to achieve sufficient disease control to bridge to transplant, not to cure with chemotherapy alone.
Alternative Considerations
For Patients Ineligible for Intensive Salvage
- Hypomethylating agents (azacitidine, decitabine) for older/unfit patients 1
- Clinical trials should be strongly considered, particularly for patients with short CR1 duration or adverse cytogenetics 1, 2
Emerging Options
- CPX-351 showed benefit in secondary/therapy-related AML in the relapsed setting (poor-risk stratum by EPI) 1
- Venetoclax-based combinations are increasingly used in the relapsed setting, though not specifically addressed in these guidelines 3
Common Pitfalls
- Delaying HLA typing: Donor search must begin immediately upon relapse, not after salvage chemotherapy response assessment
- Using standard-dose cytarabine for salvage: High-dose cytarabine is essential for salvage; standard doses are inadequate 1
- Attempting cure with chemotherapy alone: Without allogeneic HCT, long-term survival is extremely rare in relapsed AML 2
- Ignoring cardiac function: Anthracycline re-exposure requires cardiac assessment; use MEC if cardiac dysfunction present 1
The evidence consistently demonstrates that salvage chemotherapy serves as a bridge to allogeneic HCT, which remains the only potentially curative approach for relapsed AML 1, 2.